Osimertinib (AZD9291)

For research use only. Not for use in humans.

製品コードS7297

Osimertinib (AZD9291)化学構造

CAS No. 1421373-65-0

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.

サイズ 価格(税別) 在庫  
JPY 18100 あり
JPY 24400 あり
JPY 118200 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(205)

製品安全説明書

EGFR阻害剤の選択性比較

生物活性

製品説明 Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
特性 Orally bioavailable mutant-selective EGFR inhibitor that has been tested in Phase III clinical trials for treatment of Non-Small Cell Lung Cancer.
ターゲット
L858R/T790M EGFR [1]
(LoVo cells)
Exon 19 deletion EGFR [1]
(LoVo cells)
WT EGFR [1]
(LoVo cells)
11.44 nM 12.92 nM 493.8 nM
体外試験

AZD9291 shows significantly more potent inhibition of proliferation in mutant EGFR cell lines compared to wild-type in vitro. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC-9/BRc1 Mkn1SpVv[3Srb36gRZN{[Xl? NGjhVGY2OCCwTR?= NHjwUmszPCCq M3HaWWROW09? MmfzbY5lfWOnczDlfJBz\XO|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2= M33adFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEe3N|I2Lz5{NUS3O|MzPTxxYU6=
PC-9/ERc1 M1LRWGZ2dmO2aX;uJGF{e2G7 NIX1PGM2OCCwTR?= M1T2[lI1KGh? NXP4PFBPTE2VTx?= MULpcoR2[2W|IHX4dJJme3Orb36gc4YhfGinIIDyc4Fxd3C2b4TpZ{BDS0xvMjDmZY1qdHlibXXtZoVzKEKLTR?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
VP-2 NYS1RllXTnWwY4Tpc44hSXO|YYm= MUK1NEBvVQ>? NUSwVVVkOjRiaB?= MUfEUXNQ MmTabY5lfWOnczDlfJBz\XO|aX;uJI9nKHSqZTDwdo9ieG:ydH;0bYMhSkOOLUKg[oFucWy7IH3lcYJmeiCESV2= NWXneVg6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC-9/BRc1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLQOVAhdk1? MmDYNVAh\A>? MXzEUXNQ NF71ZYRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR5N{OyOUc,OjV2N{ezNlU9N2F-
PC-9/ERc1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fubVUxKG6P NFmyZo8yOCCm M362O2ROW09? MVvpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHzvcocufGW{bTCoNVAu\GG7KTDndo94fGhiaX7obYJqfGmxbjDhd5NigXN? MojEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2N{ezNlUoRjJ3NEe3N|I2RC:jPh?=
VP-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX6cIU2OCCwTR?= MUixNEBl NHvCTnNFVVOR NH;a[HdqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIxwdmdvdHXycUApOTBvZHH5LUBoem:5dHigbY5pcWKrdHnvckBie3OjeYO= NYDaWY5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0O|c{OjVpPkK1OFc4OzJ3PD;hQi=>
PC9 GR4 NGfhfG1HfW6ldHnvckBCe3OjeR?= MnPJNE0yOCEQvF2= M4fJ[VczKGh? NIPIR3NqdmirYnn0d:KhTUeIUjDwbI9{eGixconsZZRqd25iYX7kJIRwf26|dILlZY0he2mpbnHsbY5oyqB? MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl2OE[zN{c,OjV7NEi2N|M9N2F-
PC9 M2DubGZ2dmO2aX;uJGF{e2G7 NYHwNo45OC1zMDFOwG0> NXjn[XJJPzJiaB?= MUTpcohq[mm2czDXWEBGT0[UIHH0JIxwfyClb37j[Y51emG2aX;udy=> M3fZcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUS4OlM{Lz5{NUm0PFY{OzxxYU6=
PC9 GR4 NVn0c4hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmezNE0yOCEQvF2= NH7Fcms4OiCq NFP2[2JqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 NUHUOlQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5OFg3OzNpPkK1PVQ5PjN|PD;hQi=>
BAF3 NX3PXJRsTnWwY4Tpc44h[XO|YYm= NUXkNXVxPzJiaB?= MVHHTVUxKD1iMD6wNFA{KM7:TR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3 MYLGeY5kfGmxbjDhd5NigQ>? M3PnclczKGh? MXnHTVUxKD1iMD6wNFA{KM7:TR?= NFH6U3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3 Ml3lSpVv[3Srb36gZZN{[Xl? M1HnVVczKGh? NYG1PHo4T0l3MDC9JFAvODBzIN88US=> M3TkNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
HCC827 MojCSpVv[3Srb36gZZN{[Xl? NW\zRmVVPzJiaB?= M{S5[mdKPTBiPTCwMlAxOSEQvF2= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9 NVTMcpNQTnWwY4Tpc44h[XO|YYm= NYXsVmxsPzJiaB?= NIj0fmhIUTVyIE2gNE4xODJizszN MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3 NYjtR4NRTnWwY4Tpc44h[XO|YYm= MUK0JIg> NU\zZXVKTUN3MDC9JFAvODB{IN88US=> NFXhUFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827 M2DTXWZ2dmO2aX;uJIF{e2G7 MonvN{Bp MkXxTWM2OCB;IECuNFAzPSEQvF2= NEexclM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN|gzQSd-Mke0N|M5Ojl:L3G+
H1975 MYXGeY5kfGmxbjDhd5NigQ>? M4H2NlMhcA>? NHfyXndKSzVyIE2gNE4xODJ3IN88US=> NHzm[o49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN|gzQSd-Mke0N|M5Ojl:L3G+
H3255 M{j5Z2Z2dmO2aX;uJIF{e2G7 M1TOT|MhcA>? NILUdpJKSzVyIE2gNE4xODRzIN88US=> NH3uelA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{SzN|gzQSd-Mke0N|M5Ojl:L3G+
NCI-H1975 NUPDZ|Q3TnWwY4Tpc44h[XO|YYm= MV63NkBp NG\wPHVIUTVyIE2gNE4xODVizszN NGS3bIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
PC9 NET1eldCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NFr0bWQ4OiCq Mo\ETWM2OCB;IECuNFA3PSEQvF2= NWT1U4NIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O|E3PjRzPD;hQi=>
NCI-H1975 MkH5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MoXGO|IhcA>? MVLJR|UxKD1iMD6wNVA2KM7:TR?= MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDdzNk[0NUc,Ojh5MU[2OFE9N2F-
Sf21 MVfGeY5kfGmxbjDhd5NigQ>? MX;JR|UxKD1iMD6wNVIh|ryP NHy4Wm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OlI3Pyd-Mke5PVYzPjd:L3G+
PC9-DRH NI\DTlNHfW6ldHnvckBie3OjeR?= NXzpVIt5OiCq MmXNTWM2OCB;IECuNFE{KM7:TR?= NEXMOZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
BAF3 M1vsXmZ2dmO2aX;uJIF{e2G7 M2rFblczKGh? M4G2WmdKPTBiPTCwMlAyOyEQvF2= NEHQb249[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827 M4rWWmZ2dmO2aX;uJIF{e2G7 NGqwW5k6PiCq NGfU[plGSzVyIE2gNE4xOTRizszN NX;MWpp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyNlUzPjlpPkK4NlI2OjZ7PD;hQi=>
HCC827 NFvJZWNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Mk\QPVYhcA>? MkTBSWM2OCB;IECuNFE1KM7:TR?= NIjTeYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
NCI-H1975 NGq1WmxCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MVi5OkBp MWLFR|UxKD1iMD6wNVQh|ryP M1n4PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
NCI-H1975 MVnGeY5kfGmxbjDhd5NigQ>? NXOwSVVWOiCq MkXjTWM2OCB;IECuNFE2KM7:TR?= MoTVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
H1975 M{DHV2Z2dmO2aX;uJIF{e2G7 NWPBdIQ3OiCq M3;1SGlEPTBiPTCwMlAyPSEQvF2= NH\ScXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2PFI2Oyd-Mk[5OlgzPTN:L3G+
PC9 NX\vTnhDTnWwY4Tpc44h[XO|YYm= NFPGeoEzKGh? M{\5eGlEPTBiPTCwMlAyPyEQvF2= NFrwOZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2PFI2Oyd-Mk[5OlgzPTN:L3G+
NCI-H1975 MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NXjiPHJNPzJiaB?= NXvROXZmUUN3MDC9JFAvODF7IN88US=> MnjlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O|MoRjJ7NE[2O|c{RC:jPh?=
NCI-H1975 M3;JN2Z2dmO2aX;uJIF{e2G7 NVv1O|NGQTZiaB?= NVy4SpJsTUN3MDC9JFAvODF7IN88US=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
NCI-H1975 NGnIU3hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NVzQW4c6QTZiaB?= NHvl[nFGSzVyIE2gNE4xOTlizszN NHLpPG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wN|k6OSd-Mki2NFM6QTF:L3G+
NCI-H1975 NHnzNIZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M1jQOFczKGh? M2Lmd2lEPTBiPTCwMlAyQSEQvF2= Mmn5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl6NUOzOFAoRjJ7OEWzN|QxRC:jPh?=
HCC827 M3HUXGZ2dmO2aX;uJIF{e2G7 MkC4NkBp M2Hr[mlEPTBiPTCwMlAzOyEQvF2= NYPCVGNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
NCI-H1975 M2LYPGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 NWq5R|JoPzJiaB?= NF3ndXZKSzVyIE2gNE4xOjNizszN NIm5SVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N|Q6OjZ:L3G+
PC9 MW\DfZRwfG:6aXPpeJkh[XO|YYm= MXO3NkBp M3v4XmdKPTBiPTCwMlAzOyEQvF2= M{frOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975 NGHpcZlEgXSxdH;4bYNqfHliYYPzZZk> NVz4boFuPzJiaB?= NHrS[o5IUTVyIE2gNE4xOjRizszN MkC0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
HCC827 MljqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M{fVclczKGh? NHXBWohKSzVyIE2gNE4xOjV2IN88US=> NV3Fe4VtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1O|YzPzJpPkK5OVc3Ojd{PD;hQi=>
HCC827 NGXjbJdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= M{jvR|czKGh? NFfsTWNKSzVyIE2gNE4xOjdizszN NVjPSmNKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlY4PzNpPkK5OFY3Pzd|PD;hQi=>
HCC827 NY[wUWVqSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M1TJcVczKGh? NVfkWpVCUUN3MDC9JFAvODJ5IN88US=> NXHhSIhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4OVM{PDBpPkK5PFU{OzRyPD;hQi=>
NCI-H1975 Mnf5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MYO3NkBp M4LRW2lEPTBiPTCwMlA{KM7:TR?= M164eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN|U4QTxxYU6=
H3255 NWn5OldRTnWwY4Tpc44h[XO|YYm= NWj2bJhjPzJiaB?= NVj6RZNET0l3MDC9JFAvODN|IN88US=> NE\NZ|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
H3255 M3HFRWZ2dmO2aX;uJIF{e2G7 NX:yVZp7OiCq MWPJR|UxKD1iMD6wN|Yh|ryP Ml;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
NCI-H1975 MlTYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M1LFbVczKGh? NXvjVZk2UUN3MDC9JFAvODRzIN88US=> NFG0RlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N|AyQTJ:L3G+
NCI-H1975 Mlr1SpVv[3Srb36gZZN{[Xl? M1\LeFEhcA>? MXPJR|UxKD1iMD6wOFEh|ryP MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV|NEmyOkc,Ojl3M{S5NlY9N2F-
BAF3 M1HzSWZ2dmO2aX;uJIF{e2G7 MnTROEBp M2PXemVEPTBiPTCwMlA1OyEQvF2= M17FblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 MlHkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M1HlPFczKGh? MX3JR|UxKD1iMD6wOFczKM7:TR?= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV5NkK3Nkc,Ojl3N{[yO|I9N2F-
NCI-H1975 MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MXG3NkBp NY\HVJdyUUN3MDC9JFAvODV{IN88US=> NYL0S5VIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexN|E3OzlpPkK3NVMyPjN7PD;hQi=>
PC9 M4TsOWZ2dmO2aX;uJIF{e2G7 NYHGXHhHOiCq NHjE[ZFKSzVyIE2gNE4xPTZizszN NYLHSmJ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
NCI-H1975 NXzPWo03S3m2b4TvfIlkcXS7IHHzd4F6 Mn3nO|IhcA>? M4PaZWlEPTBiPTCwMlA3KM7:TR?= NVzMfZFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0PFY6PTNpPkK5OFg3QTV|PD;hQi=>
HCC827 NX30SpZFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= M{DZeGlEPTBiPTCwMlA3OTZizszN NX3ZOXlDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0NlY6QTZpPkK4OFI3QTl4PD;hQi=>
NCI-H1975 MUXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MYXJR|UxKD1iMD6wOlch|ryP MoH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
HaCaT MXXGeY5kfGmxbjDhd5NigQ>? MVSzJIg> MUnJR|UxKD1iMD6wO|M4KM7:TR?= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzR|M{iyPUc,Ojd2M{O4Nlk9N2F-
NCI-H1975 MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NH3VOoY4OiCq NYDJeVFKUUN3MDC9JFAvOTNizszN NHrO[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MESyPVk2Pid-M{C0Nlk6PTZ:L3G+
A431 MVHGeY5kfGmxbjDhd5NigQ>? NHrYW4QyKGh? NW\CUXppUUN3MDC9JFAvOTRzIN88US=> NI\GTIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWzOFkzPid-Mkm1N|Q6OjZ:L3G+
A549 MXfGeY5kfGmxbjDhd5NigQ>? NWPCOZB4UUN3MDC9JFAvOTVizszN NXPYdoRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3OVYzOjJpPkK2O|U3OjJ{PD;hQi=>
Calu3 NFfB[GFEgXSxdH;4bYNqfHliYYPzZZk> MWK3NkBp NIHje|VIUTVyIE2gNE4zPjRizszN NYTlU3hMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
Sf9 NHLTNm9HfW6ldHnvckBie3OjeR?= NU\OUJl[OjBibXnudy=> NUT6V5ZtUUN3MDC9JFAvOjd6IN88US=> NUH4XnJHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0PFIyPTFpPkK4OFgzOTVzPD;hQi=>
BAF3 NUXrdZFRTnWwY4Tpc44h[XO|YYm= NHvhdnA4OiCq NVn5UZlwT0l3MDC9JFAvOyEQvF2= NXLw[3pFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
BAF3 MYnGeY5kfGmxbjDhd5NigQ>? M{XpbFczKGh? MVLHTVUxKD1iMD6zNUDPxE1? NVLnZ5AxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H460 M{H6R2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M4PhWFczKGh? M3\ZRWlEPTBiPTCwMlQyPTlizszN NX3P[Y5rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3NVY3PDFpPkK4O|E3PjRzPD;hQi=>
LoVo NX7JW29qTnWwY4Tpc44h[XO|YYm= NVLLdIY6OiCq MkL4TWM2OCB;IECuOFgh|ryP MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl4OEK1N{c,OjZ7NkiyOVM9N2F-
LoVo MYLGeY5kfGmxbjDhd5NigQ>? NVOxR|hsOiCq MmfOTWM2OCB;IECuOFgh|ryP MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NkK2O{c,Ojd7OU[yOlc9N2F-
A549 NVLvdWlTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= MWe3NkBp NEfSNJBKSzVyIE2gNE41QDZizszN M3rRT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUe2NlczLz5{OUW3OlI4OjxxYU6=
BAF3 NF;EfopHfW6ldHnvckBie3OjeR?= MljDO|IhcA>? NVjLc2FJT0l3MDC9JFAvPSEQvF2= NY\5[3R1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A549 MXTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MX23NkBp MUDJR|UxKD1iMD61N{DPxE1? MoqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O|MoRjJ7NE[2O|c{RC:jPh?=
A549 M1fBR2N6fG:2b4jpZ4l1gSCjc4PhfS=> NE\LTpM4OiCq NG\KOI1KSzVyIE2gNE42OyEQvF2= MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
BAF3 Ml;xSpVv[3Srb36gZZN{[Xl? Mm\nO|IhcA>? MmK0S2k2OCB;IECuOVUh|ryP MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
BAF3 M1Wz[GZ2dmO2aX;uJIF{e2G7 NIrFOo04OiCq NYPG[GJsT0l3MDC9JFAvPTZizszN MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HEK293 MoDnSpVv[3Srb36gZZN{[Xl? M{faRmlEPTBiPTCwMlU4KM7:TR?= NHfSSpk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
BAF3 M4TWdWZ2dmO2aX;uJIF{e2G7 M{LNdFczKGh? MnjTS2k2OCB;IECuOVkh|ryP NXX0b|I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
A431 MkXrRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? MlfPTWM2OCB;IECuOlE2PiEQvF2= NIG1d2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
HT-29 MYnDfZRwfG:6aXPpeJkh[XO|YYm= NGPufIU4OiCq MlrVTWM2OCB;IECuOlUh|ryP MkPKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2OE[5OVMoRjJ7NEi2PVU{RC:jPh?=
A431 NVfMeGRNTnWwY4Tpc44h[XO|YYm= NUXFSHBJQTZiaB?= NVTLcZN4TUN3MDC9JFAvPjZ5IN88US=> MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ{NUK2PUc,Ojh{MkWyOlk9N2F-
A431 MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? NUHXWIdwQTZiaB?= MXjFR|UxKD1iMD62O{DPxE1? NGHTWWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEi1N|U4PSd-Mki4OVM2PzV:L3G+
A431 NUTWZmJCSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NWro[pE1PzJiaB?= MnjHTWM2OCB;IECuOlg2KM7:TR?= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV|NEmyOkc,Ojl3M{S5NlY9N2F-
A431 M4f1VWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MWq5OkBp MXfFR|UxKD1iMD63JO69VQ>? NFj2blQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[wN|k6OSd-Mki2NFM6QTF:L3G+
A549 M{LNXmN6fG:2b4jpZ4l1gSCjc4PhfS=> M{XXVVczKGh? NYfiRZJbUUN3MDC9JFAvQDdizszN MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
A431 MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5NigQ>? MUC3NkBp MXfJR|UxKD1iMD64PVMh|ryP M13aclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUOxOlM6Lz5{N{GzNVY{QTxxYU6=
BA/F3 NHzvbFFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NUPmVY9TPzJiaB?= NYO3c|RwUUN3MDC9JFEh|ryP M3vwdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MkW4OVIyLz5{NkK1PFUzOTxxYU6=
BAF3 MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoG5O|IhcA>? M13PXWdKPTBiPTCxMlIh|ryP M1nYfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H2122 Mlz2SpVv[3Srb36gZZN{[Xl? NG\DcHY4OiCq MXjHTVUxKD1iMT6yJO69VQ>? M2XIUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
A431 M1n1S2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 M4[xVVczKGh? M12yPWlEPTBiPTCxMlI1KM7:TR?= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
A431 NEHFTpBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= NXzHfoZ6PzJiaB?= MX\JR|UxKD1iMT6yOkDPxE1? NGDrUXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N|AyQTJ:L3G+
A431 M4L5UmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2G7 MnL5O|IhcA>? NUXNVoZtUUN3MDC9JFEvPjB2IN88US=> M37TXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEOzOVc6Lz5{OECzN|U4QTxxYU6=
A549 NEj0SZRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= MnnkPVYhcA>? MkTDSWM2OCB;IEGuPFMh|ryP MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
CHL NYLOUGxVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{P2SVczKGh? NH\aTplIUTVyIE2gNk46KM7:TR?= M1nJcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H1355 M2TnNmZ2dmO2aX;uJIF{e2G7 M1:xPVczKGh? NEDt[ZdIUTVyIE2gN{DPxE1? MofnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
H1703 M1TX[WZ2dmO2aX;uJIF{e2G7 NHuwPFM4OiCq M1q2T2dKPTBiPTCzMlUh|ryP Ml3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
A549 NGGxOZBHfW6ldHnvckBie3OjeR?= NHrUWlk4OiCq NYOxSHpUT0l3MDC9JFMvPSEQvF2= M{L4[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
CHO MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml7lO|IhcA>? NYnSVIVnT0l3MDC9JFQvOiEQvF2= NIf3e409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
BAF3 NWDxeGFVSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|YYm= NEHFRYE4OiCq NWjETFBGUUN3MDC9JFQvPjFizszN M37SXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5|MESyPVk2PjxxYU6=
BAF3 Mo\JRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? NYH3Roc5PzJiaB?= MW\JR|UxKD1iNT6xOUDPxE1? MofRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB2Mkm5OVYoRjNyNEK5PVU3RC:jPh?=
BEAS2B NHnsVWpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3OjeR?= Mnf4O|IhcA>? NXv1ZYpMUUN3MDC9JFE1NjlizszN Mnz4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5MU[2OFEoRjJ6N{G2OlQyRC:jPh?=
NCI-H1975 NUDXc|R6TnWwY4Tpc44h[XO|YYm= MXiyJIg> MWDJR|UxKD1iMUWg{txO MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
PC9 NUTISFFCTnWwY4Tpc44h[XO|YYm= MkLKNkBp MWXJR|UxKD1iMUeg{txO NYXNO5FzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|E6PjNpPkK1NlcyQTZ|PD;hQi=>
LoVo MV7GeY5kfGmxbjDhd5NigQ>? NYHMW5ljOiCq NWHYPYVHUUN3MDC9JFQ5OCEQvF2= M{e1eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975 NHLDflBCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= M1j1dmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOTl5NTDj[YxteyCqYYLic5JqdmdiRVfGVkBNQDV6Uj;UPVcxVSCmb4XicIUhdXW2YX70JJhmdm:pcnHmeIVlKGmwIGPDTWQhdW:3c3WgZZN{\XO|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOi53IH3nM4toN2SjeTygdI8heWRiZn;yJFch\GG7czDy[YxifGm4ZTD0c{Bkd262cn;s MlT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
rat hepatocytes MnLnSpVv[3Srb36gZZN{[Xl? NEXE[FlKdnS{aX7zbYMh[2ynYYLhcoNmKGmwIILheEBp\XCjdH;jfZRmeyCvZXHzeZJm\CCyZYKgNVAoPiClZXzsdy=> NFzUe5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+
human hepatocytes M{fs[WZ2dmO2aX;uJIF{e2G7 MV\JcpRzcW6|aXOgZ4xm[XKjbnPlJIlvKGi3bXHuJIhmeGG2b3P5eIV{KG2nYYP1doVlKHCncjCxNEc3KGOnbHzz MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ5MUm2N{c,OjV{N{G5OlM9N2F-
NCI-H1975 MnzsRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7 MVXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMhcGG{Yn;ybY5oKEWJRmKgUFg2QFJxVEm3NG0h\G:3YnzlJI12fGGwdDD4[Y5w\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCCrbnjpZol1cW:wIHH0JFUhdWdxa3ev[IF6NCCybzDx[EBnd3JiNzDkZZl{KHKnbHH0bZZmKHSxIHPvcpRzd2x? M336b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkexPVY{Lz5{NUK3NVk3OzxxYU6=
NCI-H1975 MoLKSpVv[3Srb36gZZN{[Xl? NH;x[JpU\WynY4Tpeol1gSCrbnTlfEwhemG2aX:gc4YhUUN3MDDmc5IhTUeIUjDUO|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHSxIFnDOVAh\m:{IIfpcIQhfHmyZTDFS2ZTKGW6cILld5NqdmdiaIXtZY4hSTR|MTDj[Yxtew>? NXnSVWx1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3N|AyQTJpPkK5O|MxOTl{PD;hQi=>
NCI-H1975 MU\BcpRqfHWvb4KgZYN1cX[rdImgZZN{[Xl? NVWxb5V4SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhTUeIUjDUO|kxVS:OOEW4VkBld3WkbHWgcZV1[W62IHX4dJJme3OrbnegbJVu[W5iTlPJMWgyQTd3IHPlcIx{KHinbn;ndoFnfGWmIHnuJGJCVEJxYzDheIh6dWmlIH71[IUhdW:3c3WgZZN{\XO|ZXSgZZMhfHWvb4Kg[5Jwf3SqIHnubIljcXSrb36gZZQhOTBibXevb4ctKHCxIHLp[EBnd3JiMkGg[IF6ew>? NHS2W4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUezNFE6Oid-Mkm3N|AyQTJ:L3G+
HCC827 NInEW5RCeG:ydH;zbZMh[XO|YYm= MYjJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCHN{S2MWE4PTBiZHXs[ZRqd25ibYX0ZY51KGG|c3Xzd4VlKGG|IHXhdox6KGGyb4D0c5Rq[yClZXzsd{BifCB|IIXNJIFnfGW{IEK0JIhzeyCkeTDBco5mgGmwIG[tSmlVSy:ycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7IDjSeoIhRSBzLkO0KUk> Mn7zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2Nk[3O|MoRjJ7NE[2O|c{RC:jPh?=
HCC827 MnT6RZBweHSxc3nzJIF{e2G7 NEDUXmtKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFjDR|gzPyClZXzsd{Bp[XKkb4LpcochTUeIUjDFO|Q3NUF5NUCg[IVt\XSrb36gcZV1[W62IHHzd4V{e2WmIHHzJIxifGViYYDvdJRwfGmlIHPlcIx{KGG2IEOgeW0h[W[2ZYKgNlQhcHK|IHL5JGFvdmW6aX6gWk1HUVSFL4Dyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2comgLHJ3[iB;IEK3MlE1LSl? NFXmWFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS2Olc4Oyd-Mkm0OlY4PzN:L3G+
A549 NXfFUWttTnWwY4Tpc44h[XO|YYm= M2LBXXNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKGi3bXHuJGE2PDliY3XscJMh\XiycnXzd4lv\yC5aXzkMZR6eGViRVfGVk9MNVKjczDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGW6cILld5NqdmdiRVfGVkBNQDV6Uj;UO|kxVSCmb4XicIUhdXW2YX70 MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR6Nkm1N{c,Ojl2OE[5OVM9N2F-
HCC827 MoHYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{[Xl? M3z1SlczKGh? NHrqT2JCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDR|gzPyClZXzsd{BifCBzIIXNJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmgdoVt[XSrdnWgeI8h[2:wdILvcC=> MmX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3N{[yO|IoRjJ7NUe2NlczRC:jPh?=
BAF3 MlTlSpVv[3Srb36gZZN{[Xl? NWjVTXdIOiCq MoXxTY5pcWKrdHnvckBw\iCHR1\SJHQ4QTCPL1y4OVhTN0N5OUfTJI12fGGwdDCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBud3W|ZTDCRWY{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDFS2YucW6mdXPl[EBz\WOncITvdkBxcG:|cHjvdplt[XSrb36gZZQhOSC2bzCzJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhTUeIIIP0bY12dGG2aX;uJIZweiBzNTDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODR{OUm1Okc,OzB2Mkm5OVY9N2F-
BAF3 MnfQSpVv[3Srb36gZZN{[Xl? NG\yTIMzKGh? Mn;aTY5pcWKrdHnvckBw\iCHR1\SJFE6TC:WN{mwUU9EPzl5UzDteZRidnRiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gcY92e2ViQlHGN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iRVfGMYlv\HWlZXSgdoVk\XC2b4KgdIhwe3Cqb4L5cIF1cW:wIHH0JFEhfG9iMzD1UUBxemWrbnP1ZoF1\WRiZn;yJFIhcHK|IH\vcIxwf2WmIHL5JGVITiC|dHnteYxifGmxbjDmc5IhOTVibXnud{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= M17j[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyNEK5PVU3Lz5|MESyPVk2PjxxYU6=
NCI-H1975 M4LWbmFvfGm2dX3vdkBi[3Srdnn0fUBie3OjeR?= NH\qVY9CdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNieHXuc4dz[W[2ZXSgbY4hW1SRQ1utSo95djGwdT;ObpUhdnWmZTDtc5V{\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHS3bX;yJIdzd3e2aDDheEAzOCCvZz;r[{9l[XluIIDvJJFlKG[xcjCxOEBl[Xm|IILlcIF1cX[nIITvJJVvfHKnYYTl[EBkd262cn;s Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|OUWyNVkoRjJ6M{m1NlE6RC:jPh?=
Caco2 NUm1VHlMTnWwY4Tpc44h[XO|YYm= NVvYfoJbOiCq NVrGTFViTW[obIX4JJJifGmxIH;mJIFxeGG{ZX70JJBmem2nYXLpcIl1gSCocn;tJIJie2:uYYTldoFtKHOrZHWgeI8h[XCrY3HsJJNq\GVib4\ldkBieGmlYXygd4ll\SC2bzDiZZNwdGG2ZYLhcEB{cWSnIH;2[ZIhcW5iaIXtZY4hS2Glb{KgZ4VtdHNiYYSgOUB2VSCrbnP1ZoF1\WRiZn;yJFIhcHK| NUG4Z5BoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4OVM2PzVpPkK4PFU{PTd3PD;hQi=>
A431 MUXGeY5kfGmxbjDhd5NigQ>? M3rqO3NmdGWldHn2bZR6KHKjdHnvJI9nKEWFNUCg[o9zKGi3bXHuJGE1OzFiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRVfGVkB1dyCHQ{WwJIZweiCqdX3hckBPS0lvSEG5O|Uh[2WubIOgbIFz[m:{aX7nJGVITlJvTEi1PHIwXDd7MF2g[I92[mynIH31eIFvfA>? MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh3M{W3OUc,Ojh6NUO1O|U9N2F-
Caco2 NEjP[WhHfW6ldHnvckBie3OjeR?= MV:yJIg> MofvRZBx[XKnboSgdIVzdWWjYnnsbZR6KGGlcn;zd{BieGmlYXygeI8h[mG|b3zheIVz[Wxic3nk[UBqdiCqdX3hckBE[WOxMjDj[YxteyCjdDC1JJVOKGmwY4XiZZRm\CCob4KgNkBpenN? M{O4VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
Caco2 MVXGeY5kfGmxbjDhd5NigQ>? M{fqflIhcA>? MVjBdJBiemWwdDDw[ZJu\WGkaXzpeJkh[WO{b4PzJIJie2:uYYTldoFtKHSxIHHwbYNidCC|aXTlJIlvKGi3bXHuJGNi[29{IHPlcIx{KGG2IEWgeW0hcW6ldXLheIVlKG[xcjCyJIhzew>? M2XrVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEWzOVc2Lz5{OEi1N|U4PTxxYU6=
NCI-H1975 MnPrSpVv[3Srb36gZZN{[Xl? NHfIfIs1KGh? M1LFeWlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO|kxVSCvdYThcpQhcW5iaIXtZY4hVkOLLVixPVc2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDBb5QheGixc4Doc5J6dGG2aX;uJIF1KFSqckOwPE9U\XJ2N{Ogd4l1\SCjdDCxJJVOKG2nYYP1doVlKGGodHXyJFQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
HCC827 M3;2dmZ2dmO2aX;uJIF{e2G7 NEnMZnA1KGh? NXm3eXoyUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JIlvKGi3bXHuJGhESzh{NzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hSWu2IIDoc5NxcG:{eXzheIlwdiCjdDDUbJI{ODhxU3XyOFc{KHOrdHWgZZQhOSC3TTDt[YF{fXKnZDDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NXO0enB[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFIyOjJpPkK4NlgzOTJ{PD;hQi=>
NCI-H1975 NVi1WZp4SXCxcITvd4l{KGG|c3H5 MYi0PEBp M3n5WWlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmOyClbHXheoFo\SCjdDCxJJVOKGGodHXyJFQ5KGi{czDifUBqdW23bn;icI91fGmwZx?= MnLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEKxNlIoRjJ6MkiyNVIzRC:jPh?=
HCC827 NXnxV4tSSXCxcITvd4l{KGG|c3H5 Mkf3OFghcA>? MYDJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEiFQ{iyO{Bk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne= MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
PC9 NEnJbmtCeG:ydH;zbZMh[XO|YYm= NWHMRXdFPDhiaB?= NHvhW2JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIGDDPUBk\WyuczDoZZJjd3KrbnegSWdHWiCneH;uJFE6KGSnbHX0bY9vKG23dHHueEBie3Onc4Pl[EBieyClYYPwZZNmNTNiY3zlZZZi\2ViYYSgNUB2VSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbne= M3zXdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255 NGHxZlNCeG:ydH;zbZMh[XO|YYm= MlKzOFghcA>? MoXJTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCKM{K1OUBk\WyuczDoZZJjd3KrbnegSWdHWiCOOEW4VkBufXSjboSgZZN{\XO|ZXSgZZMh[2G|cHHz[U0{KGOuZXH2ZYdmKGG2IEGgeW0h[W[2ZYKgOFghcHK|IHL5JIludXWwb3Lsc5R1cW6p M2Pv[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
NCI-H1975 NUm4SldwSXCxcITvd4l{KGG|c3H5 M{\pOFQ5KGh? M{LXW2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWgyQTd3IHPlcIx{KGijcnLvdolv\yCHR1\SJGw5PTiUL2S3PVBOKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o M{f3e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
PC9 NUHkV2V2SXCxcITvd4l{KGG|c3H5 MW[0PEBp Mmm1TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCSQ{mgZ4VtdHNiaHHyZo9zcW6pIFXHSnIh\XixbjCxPUBl\WyndHnvckBufXSjboSgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZTDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCrbX31co9jdG:2dHnu[y=> NEnjN3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK4NlEzOid-MkiyPFIyOjJ:L3G+
HCC827 MkHURZBweHSxc3nzJIF{e2G7 Mni5OFghcA>? M1q0Xmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIHX4c44hOTliZHXs[ZRqd25ibYX0ZY51KGG|c3Xzd4VlKGG|IGDBVnAh[2ynYY\h[4Uh[XRiMTD1UUBi\nSncjC0PEBpenNiYomgbY1ufW6xYnzveJRqdmd? M3fYd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkiyNVIzLz5{OEK4NlEzOjxxYU6=
H3255 M3nDeGFxd3C2b4Ppd{Bie3OjeR?= M1\NcFQ5KGh? NFTlN3JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFizNlU2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTKG23dHHueEBie3Onc4Pl[EBieyCSQWLQJINt\WG4YXflJIF1KDFidV2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5o MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDJ6MkGyNkc,Ojh{OEKxNlI9N2F-
NCI-H1975 NXKxVo83TnWwY4Tpc44h[XO|YYm= NXW2ZmJkW2WuZXP0bZZqfHlicnH0bY8hd2ZiSVO1NEBnd3JiaIXtZY4hVkOLLVixPVc2KGOnbHzzJIhiemKxcnnu[{BGT0[UIFy4OVhTN1R5OUDNJIRwfWKuZTDteZRidnRidH:gTWM2OCCob4KgbJVu[W5iQUSzNUBk\WyuczDoZZJjd3Krbnege4lt\C22eYDlJGVITlJ? NED6WYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
human hepatocytes MoHGSpVv[3Srb36gZZN{[Xl? NYfReWZIUW62cnnud4lkKGOuZXHyZY5k\SCrbjDoeY1idiCqZYDheI9kgXSnczDhd5Nme3OnZDDw[ZIhdWmubHnvckBk\Wyucx?= NF\ZUpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OESyOlk6Pid-Mki0NlY6QTZ:L3G+
rat hepatocytes NY[ydpdFTnWwY4Tpc44h[XO|YYm= MYjJcpRzcW6|aXOgZ4xm[XKjbnPlJIlvKHKjdDDo[ZBifG:leYTld{Bie3Onc4Pl[EBx\XJibXnscIlwdiClZXzsdy=> MnPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2Mk[5PVYoRjJ6NEK2PVk3RC:jPh?=
A549, NCI-H1975 MUfGeY5kfGmxbjDhd5NigQ>? M{\UeHNmdGWldHn2bZR6KHKjdHnvJI9nKEmFNUCg[o9zKEWJRj3zeIlufWyjdHXkJJdqdGRidInw[UBGT0[UIHnuJIh2dWGwIFG1OFkh[2WubIOgeI8hUUN3MDDmc5IhTUeIUjDMPFU5Wi:WN{mwUUBld3WkbHWgcZV1[W62IHnuJIh2dWGwIF7DTU1JOTl5NTDj[Yxtew>? M3zYXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
A549, PC9 MVHGeY5kfGmxbjDhd5NigQ>? MWDT[Yxm[3Srdnn0fUBz[XSrbzDv[kBKSzVyIH\vdkBGT0Zvc4TpcZVt[XSnZDD3bYxlKHS7cHWgSWdHWiCrbjDoeY1idiCDNUS5JINmdGy|IITvJGlEPTBiZn;yJGVITlJiZHXs[ZRqd25ibYX0ZY51KGmwIHj1cYFvKFCFOTDj[Yxtew>? M2fsXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
HCC827 NFHpelNCeG:ydH;zbZMh[XO|YYm= M2H5e2lv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iSFPDPFI4KGOnbHzzJIhiemKxcnnu[{BGT0[UIFW3OFYhfG9iQUe1NEBl\WyndHnvckBufXSjboSgZZN{\XO|ZXSgZZMh\WG{bImgZZBweHSxdHnjJINmdGy|IHH0JFMhfU1iYX\0[ZIhOjRiaILzJIJ6KEGwbnX4bY4hXi2ISWTDM5Bzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRiZnzve{BkgXSxbXX0dpkhMFK4YjC9JFEvOzRidH:gNU43PyVr MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh3M{O0NEc,Ojl6NUOzOFA9N2F-
NCI-H1975 NVLINVBlTnWwY4Tpc44h[XO|YYm= M2j2SGlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO|kxVSCmb4XicIUhdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBGT0Zvc4TpcZVt[XSnZDDoeY1idiCQQ1mtTFE6PzViY3XscJMh[XRiMTD0c{AyODBibl2gZpkhX2W|dHXyckBjdG:2IH3leIhw\A>? MknyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7ME[xNVQoRjJ7OUC2NVE1RC:jPh?=
A431 Mn60SpVv[3Srb36gZZN{[Xl? MVPT[Yxm[3Srdnn0fUBz[XSrbzygdoF1cW9iSVO1NEBnd3JiaIXtZY4hSTR|MTDj[YxteyCxdnXy[ZhxemW|c3nu[{B4cWymLYT5dIUhTUeIUjD0c{BKSzVyIH\vdkBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKFR5OUDNM2w5PTiUIH31eIFvfA>? NID2[IM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{GzNVY{QSd-MkexN|E3Ozl:L3G+
PC9 NEnQUppCdnSrdIXtc5Ih[WO2aY\peJkh[XO|YYm= MnH5RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO5JINmdGy|IHjhdoJwemmwZzDFS2ZTKGW6b36gNVkh\GWuZYTpc44h[WO2aY\heIlv\yCvdYThcpQhgGWwb3fyZYZ1\WRiaX6gV2NKTCCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCBzMDDt[{9s\y:mYYmsJJBwKHGmIH\vdkA4KGSjeYOgdoVt[XSrdnWgeI8h[2:wdILvcC=> MoTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{G5OlMoRjJ3MkexPVY{RC:jPh?=
A431 MnjLRY51cXS3bX;yJIFkfGm4aYT5JIF{e2G7 NWrWc|JOSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVQ{OSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDTR2lFKG2xdYPlJIF{e2W|c3XkJIF{KHS3bX;yJIdzd3e2aDDpcohq[mm2aX;uJIF1KDVibXevb4cw\GG7LDDwc{By\CCob4KgO{Bl[Xm|IILlcIF1cX[nIITvJINwdnS{b3y= NHLIRVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3NVk3Oyd-MkWyO|E6PjN:L3G+

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
p-EGFR / p-AKT / p-ERK; 

PubMed: 28416483     


PC-9/BRc1 cells were treated with the indicated doses of osimertinib. Drugs were refreshed every 24 hours. Cellular lysates were probed with the indicated antibodies. Osim: osimertinib.

ABCB1; 

PubMed: 27649127     


The effect of osimertinib at 0.3 μM on the expression of ABCB1 was measured in KB-3-1 and KB-C2 cell lines for 0, 24, 48, and 72 h.

28416483 27649127
Growth inhibition assay
Cell viability; 

PubMed: 31043587     


Cells were treated with gefitinib or osimertinib for 72 h. Cell viability was measured by MTT assay. *P < 0.05, **P < 0.01, ***P < 0.005 by t-test.

31043587
Immunofluorescence
Ki67 / γH2AX / p16; 

PubMed: 29212784     


PC9ER cells were treated for 5 days with either 3×mAbs (20 μg/ml), saline (CTRL), or with a low dose of osimertinib (2.5 nM). Shown are representative images of cells fixed in paraformaldehyde and immunostained for KI67 (panel E), γH2AX (panel F), and p16 (panel G). DAPI counterstaining was used to follow nuclear localization. Scale bar, 20 μm. The box and whisker plots, where the ends of the box are the upper and lower quartiles, depict quantifications of results obtained in three independent experiments. **P ≤ 0.01, ***P ≤ 0.001, n = 4; one-way ANOVA with Tukey's test.

29212784
体内試験 AZD9291(5mg/kg p.o.) causes profound regression of tumors across EGFRm+ (PC9) and EGFRm+/T790M (H1975) tumor models with profound inhibition of EGFR phosphorylation and key downstream signaling pathways such as AKT and ERK in vivo. [2]

お薦めの試験操作(参考用のみ)

動物試験:

[2]

- 合併
  • 動物モデル: Mice bearing PC9 and H1975 xenograft tumors
  • 投薬量: ~5 mg/kg
  • 投与方法: p.o.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 99 mg/mL (198.15 mM) warming
Ethanol 43 mg/mL warmed (86.06 mM)
Water Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
混合させたのち直ちに使用することを推奨します。
7.5mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 499.61
化学式

C28 H33 N7 O2

CAS No. 1421373-65-0
Storage powder
in solvent
別名 N/A
Smiles CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02841579 Completed Drug: Osimertinib Non-Small Cell Lung Cancer MedSIR|AstraZeneca August 2016 Phase 2
NCT02771314 Active not recruiting Drug: AZD9291 Non Small Cell Lung Cancer Hellenic Oncology Research Group August 2 2016 Phase 2
NCT02511106 Active not recruiting Drug: AZD9291 80 mg/40 mg|Drug: Placebo AZD9291 80 mg/40 mg Stage IB-IIIA Non-small Cell Lung Carcinoma AstraZeneca October 21 2015 Phase 3
NCT02529995 Completed Drug: AZD9291 40 mg|Drug: AZD9291 80 mg Carcinoma Non-Small-Cell Lung With EGFR Mutation Positive AstraZeneca August 24 2015 Phase 1
NCT02491944 Completed Drug: AZD9291|Drug: [14C]AZD9291 Oncology AstraZeneca July 2015 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Can this formulation be used in mice? What are reconstitution instructions for in vivo with mice?

  • 回答:

    Osimertinib can be used for animal study. The vehicle we suggest is: 1% DMSO+30% PEG 300+dd H2O at up to 30mg/ml.

EGFRシグナル伝達経路

相関EGFR製品

Tags: Osimertinib (AZD9291)を買う | Osimertinib (AZD9291) ic50 | Osimertinib (AZD9291)供給者 | Osimertinib (AZD9291)を購入する | Osimertinib (AZD9291)費用 | Osimertinib (AZD9291)生産者 | オーダーOsimertinib (AZD9291) | Osimertinib (AZD9291)化学構造 | Osimertinib (AZD9291)分子量 | Osimertinib (AZD9291)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID